Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements (Tables)

v3.20.4
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.

 

    As of December 31, 2019     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2019  
    Amount     Value     Level 1     Level 2     Level 3  
                               
Liabilities:                                        
Contingent consideration:                                        
Asuragen (1)   $ 2,893     $ 2,893     $   -     $    -     $ 2,893  
Other long-term liabilities:                                        
Warrant liability (2)     82       82       -       -       82  
    $ 2,975     $ 2,975     $ -     $ -     $ 2,975  

 

    As of December 31, 2018     Fair Value Measurements  
    Carrying     Fair     As of December 31, 2018  
    Amount     Value     Level 1     Level 2     Level 3  
Liabilities:                                        
Contingent consideration:                                        
Asuragen   $ 3,127     $ 3,127     $ -     $     -     $ 3,127  
Other long-term liabilities:                                        
Warrant liability     361       361       -       -       361  
    $ 3,488     $ 3,488     $ -     $ -     $ 3,488  

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement.

 

                      Cancellation     Adjustment        
                      of Obligation/     to Fair Value/        
    December 31, 2018     Payments     Accretion     Conversions Exercises     Mark to Market     December 31, 2019  
       
Asuragen   $ 3,127     $ (630 )   $ 440     $            -     $ (44 )   $ 2,893  
                                                 
Underwriters Warrants     361       -       -       -       (279 )     82  
    $ 3,488     $ (630 )   $ 440     $ -     $ (323 )   $ 2,975